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Abstract
Introduction: Preclinical testing in animal models is a critical component of the drug
discovery and development process. While hundreds of interventions have demonstrated preclinical efficacy for ameliorating cognitive impairments in animal models,
none have confirmed efficacy in Alzheimer’s disease (AD) clinical trials. Critically this
lack of translation to the clinic points in part to issues with the animal models, the preclinical assays used, and lack of scientific rigor and reproducibility during execution. In
an effort to improve this translation, the Preclinical Testing Core (PTC) of the Model
Organism Development and Evaluation for Late-onset AD (MODEL-AD) consortium
has established a rigorous screening strategy with go/no-go decision points that permits unbiased assessments of therapeutic agents.
Methods: An initial screen evaluates drug stability, formulation, and pharmacokinetics
(PK) to confirm appreciable brain exposure in the disease model at the pathologically
relevant ages, followed by pharmacodynamics (PD) and predictive PK/PD modeling to
inform the dose regimen for long-term studies. The secondary screen evaluates target engagement and disease modifying activity using non-invasive positron emission
tomography/magnetic resonance imaging (PET/MRI). Provided the compound meets
its “go” criteria for these endpoints, evaluation for efficacy on behavioral endpoints are
conducted.
Results: Validation of this pipeline using tool compounds revealed the importance of
critical quality control (QC) steps that researchers need to be aware of when executing preclinical studies. These include confirmation of the active pharmaceutical ingredient and at the precise concentration expected; and an experimental design that is
well powered and in line with the Animal Research Reporting of In vivo Experiments
(ARRIVE) guidelines.
Discussion: Taken together our experience executing a rigorous screening strategy
with QC checkpoints provides insight to the challenges of conducting translational
studies in animal models. The PTC pipeline is a National Institute on Aging (NIA)supported resource accessible to the research community for investigators to
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nominate compounds for testing (https://stopadportal.synapse.org/), and these
resources will ultimately enable better translational studies to be conducted.
KEYWORDS

Alzheimer’s disease, drug screening, mouse models, preclinical testing, translational approaches

1

INTRODUCTION

preclinical screening of therapeutic compounds, and importantly prioritizes PK and pharmacodynamics (PD) measures over cognitive mea-

Throughout the last several decades there have been considerable

sures as the primary screen in mouse models.8,9 Critically, all raw and

efforts to develop disease-ameliorating treatments which stop, pre-

analyzed data, including negative and positive findings, are reported to

vent, or delay Alzheimer’s disease (AD).1,2 Unfortunately, while hun-

the public data repository (https://adknowledgeportal.synapse.org/).

dreds of interventions from a range of drug classes have shown preclinical efficacy in ameliorating cognitive impairment and disease burden
in animal models, none to date have proven efficacious for improving

2

METHODS

cognition in human clinical trials.2-4
Preclinical testing in animal models is a critical component of the

The PTC has established a rigorous screening strategy with a pri-

drug discovery and development process, to predict both a compound’s

ori go/no-go decision points that allow unbiased assessments of

efficacy and safety profile in the clinic. Historically, preclinical screen-

potential therapeutic agents and critical quality control (QC) check-

ing of test compounds for AD have used behavioral endpoints in rodent

points as part of best practices (Figure 1). As part of establish-

models as the primary screen.4 A review of the literature and the

ing this screening strategy, to optimize protocols and validate the

Alzheimer’s disease preclinical efficacy database AlzPED (see https:

pipeline, the PTC evaluated a well-characterized clinical tool com-

//alzped.nia.nih.gov), provides insight into these preclinical behavioral

pound, the beta-secretase one inhibitor MK-8931 (verubecestat). In

studies which have often been misinterpreted, including ignoring con-

line with the PTC’s precision medicine approach, the mechanism of

founds of hyperactivity and visual impairments on cognitive behav-

action of verubecestat was matched to a well-characterized model

iors in aging animals, along with failure to determine pharmacokinetics

system with a relevant AD biomarker (eg, robust amyloid deposition)

(PK) in the model system.5 These experiments have frequently failed

that enabled in vivo target engagement; 5XFAD mice (B6.Cg-Tg [APP-

to transparently report critical details of the experimental design,

SwFlLon,PSEN1*M146L*L286V]6799Vas/Mmjax; JAX#34848). Prior

including rigor in methods for blinding, randomization, counterbalanc-

to initiating long term chronic dosing studies, qualification and

ing, inclusion of appropriate controls, and statistically powered sam-

confirmation of the active pharmaceutical ingredient (API) by liq-

ple size selection, which are fundamental aspects of Animal Research

uid chromatography-mass spectrometry (LC/MS/MS) was performed,

Reporting of In vivo Experiments (ARRIVE) guidelines.5-8

Further, test-

along with drug formulation and stability assessments. Once con-

ing has often been conducted in young animals, and often limited to

firmed, PK studies were conducted in 5XFAD mice (n = 3–4 per

only one sex. Moreover, preclinical AD studies have rarely used molec-

sex/dose) at pathophysiological relevant ages (eg, 6 months) to con-

ular biomarkers, or other clinically translational endpoints as PD read-

firm brain exposure. Predictive PK/PD modeling was conducted to

outs (ie, positron emission tomography/magnetic resonance imaging

inform the study design, including optimal dosing regimens (ie, dose,

[PET/MRI]). While there is value in functional, symptom-modifying out-

route, frequency) for long-term PD studies. After the primary screen,

come measures, these should be considered once biomarker changes

non-invasive PET/MRI were conducted to evaluate target engagement

have been shown to result in a dose-, or concentration-, dependent

after chronic treatment (n = 10-15 per sex/dose). For the present

manner consistent with target engagement in the tissue of interest.

studies, the clinical radio-tracer 18F-AV45 PET was used to evaluate

Indeed, while the mouse remains an important animal model system for

alterations of amyloid as the PD endpoint. Mice were injected with

evaluating potential therapeutic efficacy for AD, it is imperative that

5 to 7MBq of 18F-AV45 via tail vein, allowed 30 minutes uptake in

researchers promote responsible use of these models for preclinical

their home cages, and then scanned for 15 minutes on IndyPET3. Cor-

drug testing.

rected images (ie, decay, scatter, dead-time, etc) were reconstructed

In an effort to improve preclinical to clinical translation, the Preclin-

via filtered back-projection, registered to the Paxinos-Franklin atlas,

ical Testing Core (PTC) of the Model Organism Development for Late

27 brain regions extracted, and standardized uptake value ratio (SUVR;

Onset Alzheimer’s Disease (MODEL-AD) consortium is responsive to

ie, relative to cerebellum) values computed. Provided the compound

the 2012 and 2015 National Institute on Aging (NIA) AD Research

meets its criteria for these endpoints, evaluation of behavioral end-

Summit recommendations on increasing the predictive power of pre-

points are conducted. All experiments are conducted in line with

clinical testing in animal models.8,9 This includes establishment of rig-

the ARRIVE guidelines and carried out in line with the National

orous and standardized protocols, which implement best practices for

Institutes of Health (NIH) guide for the care and use of laboratory
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animals (NIH Publications No. 8023, revised 1978).7 All detailed methods and data including animal husbandry and breeding conditions as

RESEARCH IN CONTEXT

well as assay standard operating procedures (SOPs) are available via
1. Systematic review: The authors reviewed the literature

https://adknowledgeportal.synapse.org and www.model-ad.org.9

using traditional (eg, PubMed) and new sources (eg,
AlzPED), as well as face to face discussions with scien-

3

tists on approaches to preclinical testing in animal mod-

RESULTS

els. It was clear that a majority of studies have not been
executed with the level of rigor used in clinical trials,

The LC/MS/MS assay was developed in the Clinical Pharmacology

including gaps in methods for blinding, a priori inclu-

Analytical Core using verubecestat triflouroacetate purchased from

sion and exclusion criteria, predetermined sample sizes,

Selleck Chemicals (Cat #S8173; standard). Figure 2(A-D) shows the

randomization, and data quality control measures. Fur-

resulting LC/MS/MS chromatograms of the verubecestat standard

ther, testing is often conducted opportunistically in the

(2A) and corresponding internal standard MK-2206 (2B), and the

animal model most readily available to the laboratory,

custom batch API (2C) and corresponding MK-2206 (2D). Analysis of

rather than matching the mechanism of action to the most

the custom bulk synthesis batch of verubecestat from the same vendor

appropriate model for in vivo target engagement and rel-

was not detectable using this assay. To evaluate this discrepancy,

evant biomarkers.

the method was transferred to a liquid chromatography/ultraviolet

2. Interpretation: Our findings highlight a need for

(LC/UV) system (λ = 280 nm). Injecting both the standard and the

improved methodologies and resources for the research

custom batch revealed that the standard eluted at 8.953 minutes

community.

(2E) while the custom batch API eluted at 9.666 minutes (2F). Fur-

3. Future directions: We propose a framework for improved

ther analyses concluded that the custom batch API did not contain

rigor in preclinical testing that will ultimately enable bet-

verubecestat. The vendor subsequently replaced the custom batch

ter translation from animal models to clinical studies.

API, which was confirmed as verubecestat. Acute oral administration
to 6 months aged 5XFAD mice for PK analysis revealed a short half-life
for verubecestat (ie, T1/2 = 2.7 hours), which would require multiple
daily administrations via oral dosing over a 3-month period to maintain
targeted exposure levels in the brain. To avoid significant stress and

QC and stability testing of the API; and (2) initial PK and PD modeling

attrition related to daily oral gavage, the API was sent to a commercial

to inform the dose regimen. These initial data confirm that the API is

vendor and milled into chow. Two batches of pellets underwent QC

the intended compound, and that the dose regimen selected achieves

prior to dosing, which revealed erroneous mislabeling by the vendor.

the expected concentrations in the target tissue. Failure of either sce-

After correcting these anomalies, inter- and intra-pellet analyses

nario could result in false negative results, and months of wasted time,

were conducted to confirm drug concentration in pelleted chow.

efforts, resources, and precious animals. In the present studies, the

Inter-pellet analysis revealed an average 54 ± 17% and 59 ± 16% of

initial QC steps allowed us to correct issues with drug formulations

expected drug concentrations, in batch 1 and batch 2, respectively.

prior to advancing with the chronic study, which would have ultimately

Intra-pellet analysis revealed unequal distribution with coefficient

resulted in unexplained failure. Moreover, QC of the drug concentra-

of variation ranging from 8% to 36%. These data coupled with the

tion in the intended formulation, including in food, are critical aspects

pilot PK data provided additional information for PK/PD modeling

for success. Ideally in vivo PK should be determined prior to initiat-

to better calculate the range of drug concentrations required to be

ing long term studies to understand the kinetic properties and drug

formulated into chow to achieve adequate exposure levels in the brain.

uptake at the active site. For most AD therapies, this will include under-

The designated dose levels of 60, 100, and 600 parts per million were

standing of blood-brain barrier permeability and tissue exposure. At a

therefore formulated to achieve estimated daily dosages of 10, 30, and

minimum, the API should be assessed in plasma and brain as part of

100 mg/kg/day, fed ad libitum in chow, and were in line with our PK

the terminal procedures to confirm target exposure. Importantly, these

data and published EC50 for verubecestat.10 Subsequently, analysis of

aforementioned fail-safes permitted advancement of this study, and

chronic verubecestat exposure on amyloid levels resulted in expected

resulted in the expected dose-dependent reduction in beta amyloid as

dose dependent reductions in amyloid in both sexes as measured by

measured by 18F-AV45 PET SUVR.

18F-AV45 PET SUVR, in line with clinical findings.10

5
4

CONCLUSIONS

DISCUSSION
Evaluation of potential therapeutic efficacy of test compounds in

Like most preclinical efficacy studies for AD, our pipeline includes

animal models is not trivial. Emphasis on QC steps is an essential part

chronic dosing of test compound in aged mice. However, we also

of rigor in experimental design, and unfamiliarity of these steps is an

include several crucial steps prior to the chronic dosing, namely: (1)

unfortunate common point of failure. Our collective prior experience
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F I G U R E 1 The Model Organism Development for Late Onset Alzheimer’s Disease (MODEL-AD) Preclinical Testing Core (PTC) Drug
Screening pipeline. The PTC strategy includes a primary screen to determine: drug conformation of active pharmaceutical ingredient; formulation
and drug stability; in vivo pharmacokinetics (PK), and target tissue concentrations in models at disease-relevant ages. A secondary screen
evaluates target disease modifying activity using non-invasive positron emission tomography/magnetic resonance imaging as a pharmacodynamics
(PD) readout matched to known disease pathology in the model. Mouse models are best matched to mechanism of action of compound being
evaluated relative to model disease trajectory and pathophysiology. Compounds demonstrating positive PD effects in the secondary screen are
further interrogated via a tertiary screen of functional assays that assess the compound’s ability to normalize a disease-related phenotype in
cognition and neurophysiological tests, as well as a therapeutic index relative to any adverse effects. The final component of the PTC screen
includes confirmatory pharmacokinetics, genotyping quality control, and post treatment transcriptomics. The PTC pipeline is a National Institute
on Aging-funded resource accessible to the research community via the Screening the Optimal Pharmaceutical for Alzheimer’s Disease (STOP-AD)
program (https://stopadportal.synapse.org)

provided us knowledge of potential areas for errors in our pipeline
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F I G U R E 2 Validation of the active
pharmaceutical ingredient of verubecestat.
Chromatogram of standard verubecestat (A),
catalog S8564, and MK-2206 (B) the internal
standard injected to liquid chromatography-mass
spectrometry (LC/MS/MS) system. The filled peak
is the analyte of interest. Chromatogram of
custom batch active pharmaceutical ingredient
(API) verubecestat (C), catalog S8564, and
MK-2206 (D) the internal standard injected to
LC/MS/MS system. The filled peak is the analyte of
interest. Chromatogram of standard verubecestat
(E) at retention time 8.953 minutes, and custom
batch API verubecestat (F) at retention time 9.666
minutes determined not to be the correct API for
verubecestat, injected to liquid chromatography/
ultraviolet (LC/UV) system
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